Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC)

Clinical Trial ID NCT00390195

Rank	Title	Journal	Year	PubWeight™‹?›
1	The TOR pathway: a target for cancer therapy.	Nat Rev Cancer	2004	9.02
2	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.	Oncotarget	2011	3.43
3	Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer.	Br J Cancer	2004	2.15
4	Targeted therapy for hepatocellular carcinoma: novel agents on the horizon.	Oncotarget	2012	1.55
5	Major challenges limiting liver transplantation in the United States.	Am J Transplant	2011	1.50
6	Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer.	World J Gastroenterol	2008	1.31
7	mTOR inhibitors for hepatocellular cancer: a forward-moving target.	Expert Rev Anticancer Ther	2009	1.13
8	Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition.	Liver Cancer	2012	0.98
9	Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma.	Aliment Pharmacol Ther	2012	0.97
10	Evolving therapies in the treatment of hepatocellular carcinoma.	Biologics	2008	0.83
11	Targeted therapies in the treatment of advanced hepatocellular carcinoma.	Clin Med Insights Oncol	2013	0.83
12	Mammalian target of rapamycin.	Semin Oncol	2004	0.82
13	Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma.	BMC Cancer	2010	0.79